Cyclobenzaprine Hydrochloride
Cyclobenzaprine Hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Cyclobenzaprine Hydrochloride; Generic name: CYCLOBENZAPRINE HYDROCHLORIDE; Manufacturer: Preferred Pharmaceuticals Inc..
| Brand name | Cyclobenzaprine Hydrochloride |
|---|---|
| Generic name | CYCLOBENZAPRINE HYDROCHLORIDE |
| Manufacturer | Preferred Pharmaceuticals Inc. |
| Used for | INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration a |
| Dosage | DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than two or three weeks is not recommended. (see INDICATIONS AND USAGE ). Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS, Impaired Hepatic Function , and |
| Warnings | WARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. The concomitant use of cyclobenzaprine hydrochloride with MAO inhibitors is contraindicated (see CO |
| Active ingredient(s) | CYCLOBENZAPRINE HYDROCHLORIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=014dd648-5b84-4d1d-80fc-a467e2d741ef |